Reversible Cerebral Vasoconstriction Syndrome after Administering Etanercept during Puerperium

Our objective is to clarify relationship between reversible cerebral vasoconstriction syndrome and administrating etanercept during puerperium. Several lines of evidence have suggested tumor necrosis factor (TNF) as a mediator of vascular dysfunction associated with estrogen deficiency. A 32-year-old woman resumed etanercept (25 mg/week), a TNF inhibitor, which had been discontinued during pregnancy, because of the deterioration of rheumatoid arthritis. She was admitted to our hospital with upper right quadrant blindness and mild right hemiparesis accompanied by pulsating left occipital pain, which had appeared 4 hours after restarting etanercept (25 mg/week).

Source: Journal of Stroke and Cerebrovascular Diseases - January 9, 2019 Category: Neurology Authors: Daisuke Hara, Saki Nukui, Takahiro Shimizu, Hisanao Akiyama, Yasuhiro Hasegawa Tags: Case Report Source Type: research